Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

7
Rounds Report: Aveo Rallied As Investors Are Optimistic About TIVO-3 Future Development

15h seekingalpha
The overall bioscience market traded northbound due to the resurgence of investors' confidence. Many firms under our coverage enjoyed further gains.
GWPH AVEO NVS IBB XBI GWP

3
IOMachine Runthroughs: Buy GW Pharma On Current Approval And Future Catalysts

2018-07-17 seekingalpha
The Input-Output Machine, or IOMachine, is a new analysis tool we developed for our subscribers at the Total Pharma Tracker. This takes a biotech ticker as input and outputs an opinion based on four simple factors - one, presence of upcoming catalyst, mainly in the form of late stage lead candidate trial data or PDUFA; two; previous trial performance analysis of that lead candidate in the specific indication where it has a catalyst; three, cash and burn and general management ability to run the company through the catalyst and after; and four, competition and market potential.
GWPH ZGNX

5
Zogenix's Epilepsy Candidate Successful in Phase III Study

2018-07-13 zacks
Zogenix, Inc. (ZGNX - Free Report) announced successful completion of its second confirmatory phase III study (Study 1504) evaluating its pipeline candidate, ZX008 (low-dose fenfluramine hydrochloride), for treating Dravet syndrome, a type of epilepsy in children and young adults.
GWPH SUMM INSY ZGNX SMMT SAM GWP

3
GW Pharmaceuticals: What The Recent Epidiolex Approval Foretells

2018-07-13 seekingalpha
Sativex is being commercialized in the EU for the treatment of spasticity associated with multiple sclerosis.
GWPH GWP

56
Biotech: Take It On The Run

2018-07-05 seekingalpha
Jonathan Faison, author of ROTY on Marketplace, says his approach to biotech investing offers a framework for disciplined decision-making.
BLCM SLDB GLMD LOXO INCY ARQL NTEC KDMN SRPT MGTX AQXP 4508 IFRX MTZXF ARGX GWPH MTZPY NVS CTMX GWP

5
Best ETFs for 2018: ALPS Medical Breakthroughs ETF Keeps Rolling Along

2018-07-02 investorplace
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO).
MDGL SBIO GWPH GWP

2
GW Pharma Receives Regulatory Go Ahead: Should You Buy?

2018-07-02 seekingalpha
People vouching for marijuana legalization have been celebrating the recent green flag by the Food & Drug Administration (FDA) for the cannabis-based drug, Epidiolex. GW Pharmaceuticals (NASDAQ:GWPH), a London headquartered company is producing a drug for the treatment of epilepsy that uses cannabidiol, specifically for people suffering from Lennox-Gastaut and Dravet syndromes. Here we use TipRanks data to take a closer look at what Wall Street's top analysts see in store for this volatile stock.
GWPH GWP

4
CBD Medicine Developments Provide a Really Solid Base for GWPH Stock

2018-06-30 investorplace
Th U.S. Food and Drug Administration (FDA) approved Epidiolex June 25, a CBD medicine developed by GW Pharmaceuticals (NASDAQ:GWPH) that treats two rare forms of epilepsy.
GWPH ZTS GWP

76
6 Marijuana Stocks to Invest In for 1,000%+ Gains | InvestorPlace

2018-06-28 investorplace
Editor’s note: Below, you’ll find the third essay in Matt McCall’s multi-part series on making a fortune in the coming marijuana boom.
STZ.B PM ACBFF DTK ZYNE STZ IIPR.PRA CGC LVISF TWMJF ACB IIPR GWPH WEED KO SBUX MCD HSY GWP

52
Here’s the Reason that GWPH Stock Tumbled Despite Regulatory Victory

2018-06-27 investorplace
At first glance, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is one of those investments that should be moving higher, but it GWPH stock isn’t.
GWPH ZGNX GWP

217
Rounds Report: Axovant Rallied While The FDA Approved Epidiolex

2018-06-27 seekingalpha
We look for a horse with one chance in two of winning and which pays you three to one. - Charlie Munger
DOVA GWPH OXB IBB XBI OXBDF ONCE GWP AXON

1
Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher Concentrations and Announces Corporate Restructure

2018-06-27 globenewswire
VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in hemp-based health and wellness products, the development of pharmaceutical CBD delivery methods and the manufacturing of a pure, natural CBD as an Active Pharmaceutical Ingredient (API) for use in finished pharmaceutical products (FPPs), applauds the FDA’s decision on the long-anticipated approval of GW Pharmaceutical’s (NASDAQ: GWPH) Epidiolex for the treatment of seizures associated with two forms of epilepsy.
GWPH ISOLF

2
Marijuana News: FDA Approves First-Ever Cannabis-Based Drug

2018-06-26 investorplace
GW Pharmaceuticals (NASDAQ:GWPH) got some positive marijuana news from the U.S. Food and Drug Administration (FDA) on Monday.
GWPH GWP

48
5 Hot Marijuana Stocks as Beer Companies Shop for an Acquisition | InvestorPlace

2018-06-26 investorplace
Just when you thought the bullish phase in marijuana stocks is losing its momentum. Last week, Canada became the second country to legalize cannabis. Meanwhile, beer companies are looking to get in on the action. Bloomberg recently reported that Molson Coors (NYSE:TAP) is in talks with several weed companies about the possibility of marijuana-infused beverages. In October, Constellation Brands (NYSE:STZ), the makers of Corona and Modelo brand beers, purchase a 9.
STZ.B CRON ACBFF NYTAB STZ CGC TAP TWMJF ACB GWPH WEED OGRMF GWP OGI ABEV

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to GWPH / GW Pharmaceuticals Plc. on message board site Silicon Investor.

GWPH GW Pharmaceuticals board
CUSIP: 36197T103